Plecanatide

Summary

Plecanatide is an oral, prescription‑only peptide that activates the intestinal guanylate cyclase‑C (GC‑C) receptor. It is approved for the treatment of chronic idiopathic constipation (CIC) and is recommended, with moderate certainty, for irritable bowel syndrome with constipation (IBS‑C). By stimulating fluid secretion and accelerating colonic transit, plecanatide helps restore regular bowel movements and alleviates constipation‑related symptoms.

Mechanism of Action

Plecanatide is a synthetic analogue of uroguanylin that binds to the GC‑C receptor on the apical surface of intestinal epithelial cells. Receptor activation raises intracellular cyclic guanosine monophosphate (cGMP), which in turn activates protein kinases that phosphorylate ion channels. The resulting chloride and bicarbonate secretion draws water into the lumen, softening stool and increasing transit speed, thereby relieving constipation.

What the Research Shows

Clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology have systematically reviewed plecanatide among other agents for constipation. In two recent guideline updates (2023 and 2022), plecanatide received a strong recommendation for chronic idiopathic constipation and a conditional recommendation for IBS‑C, reflecting moderate to high certainty of benefit for CIC and lower certainty for IBS‑C. A network meta‑analysis of randomized trials including plecanatide compared its efficacy against other secretagogues and laxatives, confirming its role as an effective pro‑secretory therapy, though head‑to‑head comparisons remain limited.

Reported Benefits

Guideline evidence indicates that plecanatide improves the frequency of complete spontaneous bowel movements and reduces straining in adults with chronic idiopathic constipation, leading to better quality of life. In IBS‑C, the drug shows a modest benefit in stool consistency and abdominal discomfort, supporting its conditional recommendation. Overall, plecanatide offers a non‑stimulant, pro‑secretory option for patients who have not responded adequately to fiber or osmotic laxatives.

Limitations of the Evidence

Evidence for plecanatide in IBS‑C is less robust, resulting in a conditional rather than strong recommendation. Direct head‑to‑head trials comparing plecanatide with other GC‑C agonists or laxatives are lacking, and long‑term safety data beyond the trial periods are limited. The guidelines also note gaps in understanding optimal patient selection and comparative effectiveness, highlighting the need for further research.

Safety Considerations

The guidelines considered plecanatide’s safety profile acceptable, noting that most adverse events reported in trials were mild and transient. Diarrhoea was the most frequently observed side effect, typically mild and manageable. No serious safety concerns were identified in the cited guideline reviews, but clinicians are advised to monitor patients for excessive fluid loss and to assess tolerance during therapy.

How It Is Administered

Plecanatide is supplied as an oral tablet taken once daily, usually on an empty stomach. It is a prescription medication, and dosing is fixed; adjustments are not recommended without medical supervision. The formulation is designed for systemic absorption to act locally on the intestinal epithelium.

Routes of Administration

Goals & Uses

• Abdominal pain/discomfort reduction in IBS-CPain / Symptom ManagementModerate
• Stool consistency improvementGastrointestinalHigh
• Relief of chronic idiopathic constipation (CIC)GastrointestinalHigh
• Chronic Idiopathic ConstipationGastrointestinalHigh
• Relief of irritable bowel syndrome with constipation (IBS-C)GastrointestinalHigh
• IBS‑C (Irritable Bowel Syndrome with Constipation)GastrointestinalHigh

Contraindications

• Known or suspected mechanical gastrointestinal obstructionGastrointestinalHigh
• Hypersensitivity to plecanatide or any excipientAllergic/ImmunologicHigh
• Pediatric patients under 6 years of ageAge RelatedHigh
• Pediatric patients <6 yearsAgeHigh

Adverse Effects

• Abdominal distensionGastrointestinalUncommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Upper respiratory tract infectionInfectiousUncommon
• FlatulenceGastrointestinalUncommonExcess gas in the digestive tract
• DiarrheaGastrointestinalCommonLoose or frequent stools
• DehydrationFluid BalanceRareLoss of body water or inadequate hydration
• Abdominal painGastrointestinalCommonPain or discomfort in the abdomen

Drug Interactions

• Other laxatives (e.g., polyethylene glycol, lactulose)Moderate
• No clinically significant drug interactions identifiedLow
• Anticholinergic agentsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Breastfeeding womenReproductiveRelative
• Severe diarrheaGastrointestinalRelative
• Pediatric patients (6 to <18 years)PediatricAbsolute
• Pregnant womenReproductiveRelative
• BreastfeedingReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Chronic Idiopathic ConstipationApproved by EMA (Trulance) for constipation; IBS‑C indication pending.
• United StatesApprovedApproved: Chronic Idiopathic Constipation, IBS‑CApproved by FDA in 2017 (Trulance).
• United KingdomUnapprovedNot approved by MHRA as of knowledge cutoff.

FDA approved January 2017 for CIC; expanded approval for IBS-C in January 2018. Carries a boxed warning contraindicating use in pediatric patients under 6 years due to risk of serious dehydration. Not approved in EU or UK as of knowledge cutoff.

Evidence & Sources

• American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
  Journal ArticleLowChang L, et al.2023-01-01T00:00:00.000000Z
• AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation
  Journal ArticleLowChang L, et al.2022-01-01T00:00:00.000000Z
• American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
  Journal ArticleLowChang L, et al.2023-01-01T00:00:00.000000Z
• Evaluation and Treatment of Constipation in the Geriatric Population
  Journal ArticleModerateLucak S, Lunsford TN, Harris LA2021-01-01T00:00:00.000000Z
• Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management
  Journal ArticleModerateBlack CJ, Ford AC2018-01-01T00:00:00.000000Z
• Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
  Journal ArticleHighLuthra P, et al.2019-01-01T00:00:00.000000Z

Frequently Asked Questions